Baxter Japan Eliminates Dose Limitations On Hemophilia Treatment
This article was originally published in PharmAsia News
Baxter Japan announced April 17 that it had eliminated dose limitations to hemophilia drug Feiba from a points-to-consider treatment document. Before the change, Feiba was in principal limited to administration in patients within three consecutive days. A Ministry of Health, Labor and Welfare Insurance Bureau director's notice dated March 31 eliminated the three-day limitation. The change allows hemophilia patients a continuous administration of Feiba in situations such as surgery or heavy bleeding. (Click here for more - Japanese language
You may also be interested in...
Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.